Shares of Cytokinetics have moved -2.2% today, and are now trading at a price of $34.1. In contrast, the S&P 500 index saw a 0.0% change. Today's trading volume is 1,596,116 compared to the stock's average volume of 1,510,006.
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. Based in South San Francisco, United States the company has 409 full time employees and a market cap of $3,343,627,520.
The company is now trading -44.0% away from its average analyst target price of $60.89 per share. The 19 analysts following the stock have set target prices ranging from $41.0 to $80.0, and on average give Cytokinetics a rating of buy.
| Date Reported | Total Revenue ($ k) | Net Profit ($ k) | Net Margins (%) | YoY Growth (%) |
|---|---|---|---|---|
| 2023 | 7,815 | -526,728 | -6740 | -1539.9 |
| 2022 | 94,588 | -388,955 | -411 | -34.31 |
| 2021 | 70,428 | -215,314 | -306 | -34.8 |
| 2020 | 55,828 | -127,290 | -227 | 49.89 |
| 2019 | 26,868 | -121,692 | -453 | -34.42 |
| 2018 | 31,501 | -106,289 | -337 |
